Related references
Note: Only part of the references are listed.Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke et al.
CANCERS (2021)
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study
Michael J. Burke et al.
CLINICAL CANCER RESEARCH (2020)
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
Partbw Kebriaei et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
Uday R. Popat et al.
LANCET HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy
Masatoshi Takagi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning
Arjen. M. Punt et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2017)
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
Sung Won Choi et al.
BLOOD (2017)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Charles F. Craddock et al.
CLINICAL CANCER RESEARCH (2017)
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long Term Study Results
Partow Kebriaei et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents
Kai Xue et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Long-Term Outcomes after Treatment with Clofarabine Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome
Gheath Alatrash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
Yago Nieto et al.
CANCER (2016)
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
Imke H. Bartelink et al.
Lancet Haematology (2016)
Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia
Partow Kebriaei et al.
BLOOD (2016)
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
Yago Nieto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
Ursula Matulonis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells
Tomas Groh et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi et al.
LANCET ONCOLOGY (2015)
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
Jonathan How et al.
LEUKEMIA & LYMPHOMA (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
Michael J. Burke et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
Georg Hopfinger et al.
ANNALS OF HEMATOLOGY (2014)
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Michinori Ogura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
Roland B. Walter et al.
HAEMATOLOGICA (2014)
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer
Changhoon Yoo et al.
INVESTIGATIONAL NEW DRUGS (2014)
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan
Guiyun Song et al.
LEUKEMIA & LYMPHOMA (2014)
Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine
Je-Hwan Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
Hui Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Partow Kebriaei et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Donna M. Weber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
Benigno C. Valdez et al.
EXPERIMENTAL HEMATOLOGY (2012)
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
Benigno C. Valdez et al.
LEUKEMIA & LYMPHOMA (2012)
Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
Luca A. Petruccelli et al.
PLOS ONE (2011)
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
Peter M. Wilson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao et al.
BLOOD (2008)
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
Timothy Madden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
V. M. Richon
BRITISH JOURNAL OF CANCER (2006)
Histone deacetylase inhibitors: insights into mechanisms of lethality
RR Rosato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan plus cyclophosphamide for allogeneic bone marrow transplantation
JH Lee et al.
ANNALS OF HEMATOLOGY (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways
CR Yu et al.
CANCER BIOLOGY & THERAPY (2003)
Bayesian measures of model complexity and fit
DJ Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
JA Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
